Prenetics Global Limited Revenue Growth Rates (PRE), Current and Historic Growth - CSIMarket
CSIMarket
 


Prenetics Global Limited  (NASDAQ: PRE)
 

PRE's Revenue Growth by Quarter and Year

Prenetics Global Limited's Revenue results by quarter and year




PRE Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 91.79
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 91.79





PRE Revenue fourth quarter 2025 Y/Y Growth Comment
Prenetics Global Limited achieved in the fourth quarter 2025, above Company average Revenue surge of 201.94% year on year, to $ 91.79 millions.

Looking into fourth quarter 2025 results within Laboratory Analytical Instruments industry 20 other companies have achieved higher Revenue growth. While Prenetics Global Limited' s Revenue doubling of 201.94% ranks overall at the positon no. 3285 in the fourth quarter 2025.




PRE Revenue ( Y/Y Growth %) 2025
2024 2023 2022
4th Quarter December 201.94 % 39.83 % -92.12 % -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   201.94 % 39.83 % -92.12 % -

Financial Statements
Prenetics Global Limited's fourth quarter 2025 Revenue $ 91.79 millions PRE's Income Statement
Prenetics Global Limited's fourth quarter 2024 Revenue $ 30.40 millions Quarterly PRE's Income Statement


PRE Revenue (Quarter on Quarter Growth %)

2025
2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   201.94 % 39.83 % -92.12 % -




Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #21
Healthcare Sector #470
Overall #3285

Revenue Y/Y Growth Statistics
High Average Low
-92.12 % -92.12 % -92.12 %
(Dec 31 2023)  
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #21
Healthcare Sector #470
Overall #3285
Revenue Y/Y Growth Statistics
High Average Low
-92.12 % -92.12 % -92.12 %
(Dec 31 2023)  

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Prenetics Global Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRE's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRE's IV. Quarter Q/Q Revenue Comment


Prenetics Global Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)
12 Months Ending
(Dec 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
12 Months Ending
Cumulative Revenue 12 Months Ending $ 91.79 $ 30.40 $ 21.74 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 201.94 % 39.82 % 65.17 % - -
Year on Year Revenue Growth Overall Ranking # 3285 # 3766 # 3150 # 0 # 0
Seqeuential Revenue Change (TTM) 201.94 % 39.82 % 65.17 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 3291 # 3766 # 3922 # 0 # 0


Cumulative Revenue growth Comment
Prenetics Global Limited saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 201.94% year on year, to $ 92 millions if the fiscal year would have ended in Dec 31 2025.
Prenetics Global Limited's trailing twelve months Revenue growth was higher than company's average -92.12% and higher than 39.82% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 201.94 % increase from $30.4 millions in the period from Dec 31 2024 to .

In the Healthcare sector 469 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3285, from total ranking in previous quarter at 3766.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 21
Healthcare Sector # 470
Overall # 3285

Revenue TTM Y/Y Growth Statistics
High Average Low
-92.12 %
-92.12 %
-92.12 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 470
S&P 500 # 3291
Cumulative Revenue growth Comment
Prenetics Global Limited saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 201.94% year on year, to $ 92 millions if the fiscal year would have ended in Dec 31 2025.
Prenetics Global Limited's trailing twelve months Revenue growth was higher than company's average -92.12% and higher than 39.82% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 201.94 % increase from $30.4 millions in the period from Dec 31 2024 to .

In the Healthcare sector 469 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3285, from total ranking in previous quarter at 3766.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 21
Healthcare Sector # 470
Overall # 3285

Revenue TTM Y/Y Growth Statistics
High Average Low
-92.12 %
-92.12 %
-92.12 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 470
S&P 500 # 3291




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PRE's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Intercure Ltd 318.38%$ 318.385 millions
Vireo Growth Inc.317.81%$ 317.813 millions
Cormedix Inc 312.10%$ 312.097 millions
Galapagos Nv303.50%$ 303.502 millions
Insmed Inc287.83%$ 287.825 millions
Tscan Therapeutics Inc 286.02%$ 286.015 millions
Beam Therapeutics Inc 279.52%$ 279.516 millions
Meiragtx Holdings Plc252.33%$ 252.333 millions
Star Equity Holdings Inc 232.22%$ 232.220 millions
Ethema Health Corporation 228.03%$ 228.030 millions
Foghorn Therapeutics Inc 223.77%$ 223.775 millions
Madrigal Pharmaceuticals Inc 210.77%$ 210.766 millions
Biocryst Pharmaceuticals Inc 209.09%$ 209.087 millions
Prenetics Global Limited201.94%$ 201.941 millions
Prokidney Corp 196.05%$ 196.053 millions
Mesoblast Limited191.39%$ 191.393 millions
Northwest Biotherapeutics Inc190.91%$ 190.909 millions
Zevra Therapeutics Inc 183.36%$ 183.360 millions
Spero Therapeutics Inc 174.51%$ 174.508 millions
Taysha Gene Therapies Inc 171.27%$ 171.266 millions
Compugen Ltd161.14%$ 161.140 millions
Nyxoah Sa156.29%$ 156.287 millions
Nuo Therapeutics Inc 153.57%$ 153.570 millions
Anaptysbio Inc 151.08%$ 151.082 millions
Theravance Biopharma inc 144.70%$ 144.700 millions
Voyager Therapeutics Inc 144.28%$ 144.282 millions
Esperion Therapeutics Inc 143.73%$ 143.725 millions
Foxo Technologies Inc 141.54%$ 141.542 millions
Volitionrx Limited133.25%$ 133.247 millions
Lineage Cell Therapeutics Inc 130.40%$ 130.404 millions


About Prenetics Global Limited Revenue Growth Rates (PRE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Prenetics Global Ltd (CIK 1876431).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-028623
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Prenetics Global Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.